Martin J. Edelman, MD

Chair, Department of Hematology/Oncology

Dr. Edelman collaborates with our clinical, scientific, and administrative leadership to grow robust therapeutic, clinical research, and translational research programs in hematology and medical oncology while leading the department in evaluating emerging national trends in the delivery of care to cancer patients. In addition, Dr. Edelman is Deputy Cancer Center Director for Clinical Research, assisting a strong investigator-initiated clinical trials program.

A nationally recognized expert in the treatment and research of lung cancer, Dr. Edelman developed one of the most commonly used regimens for treating advanced lung cancer and has focused on the development of new agents and biomarkers to personalize lung cancer therapy. He has a particular interest in approaches that integrate surgery, radiation, and chemotherapy in the management of lung cancer patients.

Dr. Edelman serves on the Lung Cancer Committee of the Alliance (previously CALGB), the Board of Directors of the Alliance for Clinical Trials in Oncology, and the Thoracic Malignancies Steering Committee of the National Cancer Institute’s Scientific Review Group. In addition, he is the Medical Oncology Co-chair for the Lung Cancer Committee of the Radiation Therapy Oncology Group (RTOG) and is an active member and past chair of the Career Development and Ethics Committees of the International Association for the Study of Lung Cancer (IASLC).

Dr. Edelman has published more than 325 scientific articles, abstracts, and book chapters. In addition, he has served on the editorial boards or as an ad-hoc reviewer of numerous academic journals, including the New England Journal of Medicine and the Journal of Clinical Oncology, and currently serves as Associate Editor of the journal Lung Cancer.